AGAH Annual Meeting 2014 Mitigating risks in early medicines development
Posted:
10
January 2014
AGAH Annual Meeting 2014 Mitigating risks in early medicines development
Risk mitigation is increasingly important in early medicines development not only to allow early attrition but also to improve the chances of early drug development.Join us at the 23rd AGAH Annual Meeting taking place 13-14 March 2014 in Munich, Germany. Discussions will take into account the impact of nonclinical findings, biopharmaceutics, personalised medicine approaches, updates on safety/tolerability from a clinical pharmacology perspective, as well as early investigation of lack of efficacy.View program and register online
Futureproofing early phase clinical research for the next generation of investigators.
March 20, 2023
Richmond Pharmacology’s experienced Principal investigators and Co-investigators recently gave expert feedback on the ICH M11 (CeSHarP) protocol template.
13th International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions
Sunday, June 4th to Tuesday June 6th 2023
Exchange research-based knowledge on drug-drug interactions (DDIs) among all interested stakeholders from pharmaceutical industry, regulatory authorities, academic and health care delivery backgrounds and perspectives.
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.